Doha, March 12th 2008 The magic magnetic chair- how to facilitate best Daniela Marschall-Kehrel, Frankfurt.

Slides:



Advertisements
Similar presentations
Desmopressin: PRN Treatment in OAB Prospective, randomised, multi-centre, multinational, double-blind, placebo controlled observational study Prospective,
Advertisements

Overview of Stress Urinary Incontinence & Minimally Invasive Slings
Pelvic Floor Dysfunction
New drugs and the management of incontinence Stephen Mark.
Urinary Incontinence 1 / 18 Fletcher T. Penney, MD Medical University of South Carolina Department of Medicine.
Revolution in Asian drug development: A Korea and Japan experience Henk de Koning Gans, MD VP, Process Management Global Development Japan Pharmacia KK,
Neurourology Panele Sakineh Hajebrahimi Associate Professor of Urology TUMS.
Urinary Incontinence Kieron Durkan GPST 1.
Incontinence in children, a symptom complex Daytime incontinence (OAB), enuresis Dyschezia, incontinence for stools Pain 30-35% of these children with.
Intone: A Novel Pelvic Floor Rehabilitation Device For Urinary Incontinence Introduction Dysfunction of the pelvic floor musculature is a significant etiologic.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
BROOKLYN 2 RADIOTHERAPY Patries HERST Sat 31 st Aug 2013 Session 1 / Talk 1 09:20 – 09:46 ABSTRACT Purpose. Acute radiation-induced cystitis is a common.
OnabotulinumtoxinA for Urinary Incontinence from Neurogenic Detrusor Overactivity.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Urinary incontinence in women October Changing clinical practice NICE guidelines are based on the best available evidence The Department of Health.
Treatment of Overactive Bladder — What is Best? Presented by (insert name of presenter here)
“URINARY INCONTINENCE IN WOMEN 2013” NICE guidelines implementation in Primary Care Tony Smith Urogynaecologist St Mary’s HospitalAnson Medical CentreManchester.
Physiotherapy approaches for urgency and urge incontinence Liz Childs Pelvic Health Physiotherapist.
A Comparison of Treatment Options - The Efficacy of Endovenous Laser Ablation and Radiofrequency Ablation Therapy in the Treatment of Symptomatic Venous.
Nursing approaches for urgency and Urge Incontinence
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Urinary Incontinence in women. Urinary incontinence Stress – involuntary leakage of urine on effort, sneezing or coughing Urgency – involuntary leakage.
Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.
Elimination Elimination is the process of removing waste from the body. Hubbs Pre-CNA Elimination Unit SP2-AP2.
Disability and Incontinence Patient assessment Patient management.
Prostate VTP: Clinical Trial Update
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
Basics of outpatient depression management Chris Zamani MD.
A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Overactive Bladder Michael J. Kennelly,
Conservative treatment of faecal incontinence Jim Hill Manchester Royal Infirmary.
Sandeep Bagla, MD Cardiovascular & Interventional Radiology Inova Alexandria Hospital.
 Stephen T Jeffery University of Cape Town, South Africa Urogynaecology and laparoscopy clinic
Keeping the right patients away from hospital
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Immediate effect of transcutaneous Electrical Nerve Stimulation on Pain and flexibility in chronic nonspecific low back pain: A pilot study Authors: N.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
# 3564 Neurotoxicity with FULV versus FLOX in patients with stage II and III carcinoma of the colon: Results of NSABP Protocol C-07 S Land 1,2, J Kopec.
A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.
Reducing avoidable harm in patients with catheters
Dr Stephen Jeffery Groote Schuur Hospital Cape Town
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Val Ward Caroline Grimes Clinical Nurse Specialist: Rochester.
INTERSTIM ® THERAPY for Urinary Control. What are Bladder Control Problems? Broad range of symptoms –May leak small or large amount of urine –May leak.
COMMUNITY CONTINENCE ADVISORY SERVICE SHIRLEY BUDD CONTINENCE CLINICAL LEAD Continence Assessments 1.
Iron as a Treatment: Successes and Failures. What next? Christopher J Earley MB, BCh, PhD, FRCP(I) Professor Department of Neurology Johns Hopkins School.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized Controlled Clinical Trial of the Serotonin.
OAB / LUTS Urology Pathway for Primary Care within Frimley Health locality Developed with key local stakeholders including Urologists, Gynaecologists,
Volume 50, Issue 3, Pages (September 2006)
International Neurourology Journal 2013;17:
Volume 41, Issue 3, Pages (March 2002)
Urinary Symptoms in the Female
From: Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women Ann Intern Med. 2008;148(6):
Success of a repeated tined lead trial in a refractory OAB population
International Continence Society Introduction and aim of the study
497 MIRABEGRON IS A SAFE AND EFFECTIVE TREATMENT FOR PARKINSON’S DISEASE PATIENTS WITH STORAGE SYMPTOMS REFRACTORY TO ANTIMUSCARINICS Soto Troya I1 , Park.
Management of Male OAB; Current Status in Japan
Nasrin Changizi FPFD Fellowship
Debra E. Irwin, Ian Milsom, Zoe Kopp, Paul Abrams  European Urology 
Section III: Neurohormonal strategies in heart failure
Volume 43, Issue 4, Pages (April 2003)
Ranolazine in Microvascular Dysfunction
Pharmacotherapy in Stress and Mixed Incontinence
A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC.
Original Article Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen Susan R. Davis, M.D., Ph.D., Michele Moreau, M.D., Robin Kroll,
Economic and Social Impact of OAB
Comparison of protocols for tibial nerve electrical stimulation for the treatment of overactive bladder: clinical trial randomized blind Pierre ML, Toscano.
Women’s & Men’s Health Physiotherapy
Presentation transcript:

Doha, March 12th 2008 The magic magnetic chair- how to facilitate best Daniela Marschall-Kehrel, Frankfurt

What is evidenced based medicine? SUI post RPx: 2 Publications Mixed incontinence in both genders SUI/Qol IC/CPPS (females) SUI in females Sexual performance in women CPPS/chronic prostatitis III NIDDKD

SUI post RPx; PFMT vs MFT: n=105, 2 arms no cross over Start 1 week after catheter was removed (16.8=dry). MFT 2x20weeks 30‘ follow- up: 4 weeks, 3, 6+12mo. Continence –I: 51%, 64%, 82% –II: 44%, 50%, 68% Pad test I=p=0.004 after 12mo Qol significantly better (no numbers)

Mixed incontinence both genders n=49 24=active 25=placebo 3x6weeks; 1st: intermitt. 5Hz 10‘, 3‘rest 2nd: intermitt 50Hz 10‘; follow-up: 8weeks. Only active=14 and placebo=19 eligable SUI: –Active: pad test significant p=0.002 –Placebo: worse 47% to 68% OAB: –Urgency: active p=0.09 –Wet: active=0 (21% before), placebo=no change Pad weight –Active: mean 2.59g p=0.079 –Placebo: mean Qol –Active: p=0.04 –Placebo: p=0.56

UI 3mo post RPx n=27 11=active, 16=placebo 2x6weeks sham pat. had cross over 6wks Pads/day – 1.41 to % p>0.04; 6/9=continent –Cross over 1.89 to 1.17 Incontinence episodes –3.42 to % p>0.01 Pad weight – 4.81 to 3.81 p>0.03 –Cross over 5.78 to 1.5 p>0.05 Qol positive trends

SUI-Qol women n=66 2x6weeks 1st: 5Hz 10‘ 2nd: 50Hz 10‘ Qol –53/66 80% p=0.01 improved Incontinece episodes 40/53 0<0.01 Pad changes 46/53 p<0.01 –12/66 decreased Qol Incontinence episodes 4/12 p>0.05 Pad changes 5/12 p>0.05 Urinary frequency –20/33 decreased p=0.002 –13/33 increased p missing

IC/CPPS treatment failures n=10, investigator initiated trial 2x8weeks maximum voltage therapy 9/10 improved frequency, pain, urgency 3/10 total relief of symptoms but not long lasting 1/10 failed

SUI females n=64, follow-up 3mo n=51 2x6weeks Incontinence –18/51 34% continent Pad/day –1/day 16/51 32% 2.5 to 1.3 p=0.001 Leak episodes –3.3 to 1.7 p=0.001 UD –ALLP 43 to 48 cmH2O –DO 5/51 to 1/51 p= month follow-up n=36 –10/36 28% continent –8/36 22% 1 pad/day

Orgasmic performance in women n=20, 7/20 not sexual activ OAB wet questionaire(6 questions) n=13 6/13 no changes 2/13 worse 5/13 improved Age was most reliable (<55ys)

CPPS III NIDDKD treatment failures n=21 11=activ 10=placebo 2x4weeks 1st: cont.10Hz 15‘ 2nd: cont.50Hz 15‘ follow-up 3mo and 1y Pain score –3mo p<0.05 –1y p<0.05 Urinary symptom score –3mo p<0.05 –1y not significant

From theory to Practise

SUI Intermitt Hz 20‘ 100% 3x4-6wk +/- Duloxetin

OAB Intermitt Hz 20‘ 100% 3x4wk Antimuscarinics?

CPPS/IC Diclofenac 100mg Supp 10‘ before treatment 1st: intermitt Hz 50% 15‘min 3- 5x4weeks 2nd: cont. 5Hz 100% 15‘ see above

ED PGE5I cont., SCAT in TF? 1st: intermitt Hz 15‘ 3x4weeks 2nd:intermitt Hz 15‘ s.a.

SUI after RPx Intermitt Hz 100% 3-5x 4weeks If OAB: intermitt Hz 100% 3x4wks

CPPS/chronic Prostatitis Ciproflox 200 iv 5‘ before start MFT and 500mg evening dosage; if pain is dominant add Diclofenac 100mg Supp 10‘ before treatment Intermitt Hz 55% daily 5-10 days If pain: cont. 5Hz 100% 10‘/break 2‘/10‘ 3-5/week

No personal experience Fecal incontinence Ogasmproblems Ejaculationpower Acute pain Muscle volume